Julian Taugner
7PUBLICATIONS
2CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Nov 01, 2025
Immune checkpoint inhibition alters patterns of failure in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy.Julian Taugner, Silja Stamer, Kerstin Hofstetter
|Nov 17, 2023
First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.Kerstin Hofstetter, Julian Taugner, Lukas Käsmann
|Oct 14, 2022
Radiation-Induced Lung Injury: Prevention, Diagnostics and Therapy in the Era of the COVID-19 Pandemic.Lukas Käsmann, Julian Taugner, Alexander Nieto
|Nov 27, 2021
Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer-A Prospective Longitudinal Assessment.Diego Kauffmann-Guerrero, Julian Taugner, Chukwuka Eze
|Apr 03, 2021
Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting.Julian Taugner, Lukas Käsmann, Chukwuka Eze
|Oct 22, 2020
Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis.Monika Karin, Julian Taugner, Lukas Käsmann
Pageof 2
